XBiotech Inc
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
XBIT$1.91+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share data)
| December 31, 2023 | December 31, 2022 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $200,023 | $157,306 |
| Interest bearing time deposits | - | 60,172 |
| Accrued interest receivable | 860 | 1,216 |
| Income tax receivable | 75 | 548 |
| Prepaid expenses and other current assets | 760 | 601 |
| Total current assets | 201,718 | 219,843 |
| Property and equipment, net | 24,897 | 26,260 |
| Total assets | $226,615 | $246,103 |
| Liabilities and shareholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $2,516 | $2,408 |
| Accrued expenses | 3,501 | 1,603 |
| Income tax payable | 83 | 55 |
| Total current liabilities | 6,100 | 4,066 |
| Long-term liabilities: | ||
| Income tax payable | 1,669 | 1,576 |
| Deferred tax liability | - | 59 |
| Total liabilities | 7,769 | 5,701 |
| Shareholders’ equity: | ||
| Preferred stock, no par value, unlimited shares authorized, no shares outstanding | - | - |
| Common stock, no par value, unlimited shares authorized, 30,436,964 and 30,439,275 shares outstanding at December 31, 2023 and December 31, 2022, respectively | 271,152 | 267,325 |
| Accumulated other comprehensive income | - | 826 |
| Accumulated deficit | (52,306) | (27,749) |
| Total shareholders’ equity | 218,846 | 240,402 |
| Total liabilities and shareholders’ equity | $226,615 | $246,103 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.